Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal ...

Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal ...

Shares of Tiziana Life Sciences rose after the company said it received positive results from its nasal anti-CD3 monoclonal antibody in traumatic spinal cord injury. The stock was up 5.3% to 84 cents ...

Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies with its ...

Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal ...

Tiziana Life Sciences (TLSA) announced the discovery of new immune biomarkers in patients with non-active secondary progressive multiple ...

Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies with its ...

NEW YORK - Tiziana Life Sciences Ltd. (NASDAQ:TLSA), a biotech firm focused on immunomodulation therapies with a market ...

New York-based biotech Tiziana Life Sciences today announces its intention not to engage in a capital raising activities for the immediate future.

在其他近期新闻中，Tiziana Life Sciences在开发免疫疗法方面取得了重大进展。公司的鼻内抗CD3单克隆抗体foralumab在减轻GLP-1激动剂（常用于代谢紊乱治疗）的副作用方面显示出潜力。Tiziana的疗法旨在抵消这些激动剂的副作用，可能改善患者的长期预后。